A Single-Arm, Multicenter, Phase II Study of Camrelizumab in Relapsed or Refractory Classical Hodgkin Lymphoma - Concepedia

Concepedia

Publication | Closed Access

A Single-Arm, Multicenter, Phase II Study of Camrelizumab in Relapsed or Refractory Classical Hodgkin Lymphoma

154

Citations

17

References

2019

Year

Yuqin Song, Jianqiu Wu, Xinchuan Chen, Tongyu Lin, Junning Cao, Yanyan Liu, Yaozhong Zhao, Jie Jin, Haiwen Huang, Jianda Hu,

Clinical Cancer Research

Abstract

Camrelizumab demonstrated a high response rate, durable response and controllable safety in Chinese patients with relapsed or refractory cHL, becoming a new safe and effective treatment option in this setting.

References

	Year	Citations

Page 1